DCM
CNTA

Driehaus Capital Management’s Centessa Pharmaceuticals CNTA Stock Holding History

Driehaus Capital Management’s Portfolio CNTA Stock Details CNTA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-515,979
Closed -$12.5M – 420
2025
Q3 		$12.5M Buy
515,979
+5,200
+1% +$92.4K 0.09% 256
2025
Q2 		$6.71M Sell
510,779
-584,754
-53% -$7.41M 0.05% 290
2025
Q1 		$15.8M Sell
1,095,533
-502,650
-31% -$8.23M 0.15% 191
2024
Q4 		$26.8M Sell
1,598,183
-563,545
-26% -$9.34M 0.22% 139
2024
Q3 		$34.6M Buy
2,161,728
+69,717
+3% +$854K 0.3% 109
2024
Q2 		$18.9M Buy
2,092,011
+987,997
+89% +$9.37M 0.18% 158
2024
Q1 		$12.5M Buy
1,104,014
+814,633
+282% +$7.71M 0.12% 214
2023
Q4 		$2.3M Buy
+289,381
New +$1.94M 0.03% 292
2022
Q2 		– Sell
-1,053,142
Closed -$9.45M – 376
2022
Q1 		$9.45M Sell
1,053,142
-32,555
-3% -$297K 0.12% 241
2021
Q4 		$12.2M Buy
1,085,697
+66,897
+7% +$900K 0.12% 219
2021
Q3 		$17M Buy
1,018,800
+18,939
+2% +$392K 0.2% 156
2021
Q2 		$22.2M Buy
+999,861
New +$23.5M 0.29% 114

Other funds holding CNTA

MVM
Medicxi Ventures Management St. Helier, Jersey $177M AUM 212.06% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
IVLAV
Index Venture Life Associates VI St. Helier, Jersey $396M AUM 176.22% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
GA
General Atlantic New York $2.15B AUM 35.02% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return
TCM
TCG Crossover Management Palo Alto, California $3.5B AUM 1,165.83% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
SL
Siren LLC Greenwich, Connecticut $3.61B AUM 203.3% 1-Year Est. Return

Driehaus Capital Management's CNTA Position: Q4 2025 in Review

Driehaus Capital Management sold out of Centessa Pharmaceuticals (CNTA) in Q4 2025, closing a stake of 515,979 shares — an estimated $12.5M sold.

Driehaus Capital Management first reported a position in CNTA in Q2 2021 and held it in 12 quarters. The position peaked at $34.6M in Q3 2024. 146 funds tracked by Wall St. Rank hold CNTA as of Q4 2025.

  • Driehaus Capital Management reported no remaining Centessa Pharmaceuticals position as of Q4 2025 after selling out during the quarter.
  • Driehaus Capital Management sold 515,979 Centessa Pharmaceuticals shares in Q4 2025, an estimated $12.5M.
  • Driehaus Capital Management first reported a position in Centessa Pharmaceuticals in Q2 2021 and held it in 12 quarters.
  • Driehaus Capital Management's Centessa Pharmaceuticals position peaked at $34.6M in Q3 2024.
  • 146 funds tracked by Wall St. Rank held Centessa Pharmaceuticals as of Q4 2025.

Based on Driehaus Capital Management's 13F filing for Q4 2025, filed 17 Feb 2026.